EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness

Keita Hirai, Toshihiro Shirai, Sekiko Uehara, Taisuke Akamatsu, Kunihiko Itoh

Journal of Allergy and Clinical Immunology · 2025

DOI: 10.1016/j.jaci.2025.06.025 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Keita Hirai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Pharmacy, Shins…. Hauptthemen laut MEDLINE: Asthma, MicroRNAs, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology, Japanese Society of Allergology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Benralizumab targets IL-5 receptors and eliminates eosinophils, demonstrating its efficacy in type 2 inflammation-predominant asthma. Real-world evidence indicates variability in patient responses, emphasizing the need to understand the pathologic characteristics that influence its effectiveness. OBJECTIVE: We postulated that patients with high and low benralizumab response would exhibit distinct pathophysiologic characteristics. We aimed to identify specific genes and microRNAs (miRNAs) as potential indicators of effectiveness-related characteristics. METHODS: This prospective observational study included 17 patients with severe asthma undergoing benralizumab treatment. T-cell transcriptomic analysis was conducted before and 24 weeks after treatment initiation. To identify the genes associated with treatment efficacy, we identified differentially expressed genes (DEGs) and used a weighted gene coexpression network analysis. Additionally, serum miRNAs were analyzed quantitatively by using PCR arrays, and their correlation with gene clusters associated with treatment efficacy was investigated. RESULTS: Transcriptomic analysis revealed that 223 DEGs were included in the response to benralizumab treatment. Weighted gene coexpression network analysis identified 21 coexpressed gene clusters, with most DEGs enriched in the 2 modules. One of these modules, the magenta module, was associated with the effectiveness of benralizumab treatment. Serum miRNA profiling identified 5 miRNAs associated with both treatment effectiveness and the magenta module (miR-7-5p, miR-155-5p, miR-320b, miR-342-3p, and miR-484). Among these, miR-7-5p showed the highest predictive accuracy for benralizumab effectiveness. CONCLUSION: This study recognized specific gene expression patterns and serum miRNAs associated with the effectiveness of benralizumab in treating severe asthma. These findings contribute to our understanding of the asthma endotypes and may improve patient selection for benralizumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaMicroRNAsAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsTranscriptomeHumansMaleFemaleAdultMiddle AgedProspective StudiesGene Expression ProfilingTreatment OutcomeBiomarkersGene Regulatory Networks

Stichwörter der Autor:innen

AsthmabenralizumabbiomarkermiRNAtranscriptome

Substanzen

benralizumabMicroRNAsAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Matsumoto, Japan; Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan; Department of Clinical Pharm…
  • Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
  • Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Clinical Pharmacology and Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan; Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.

Förderung

  • Japan Research Foundation for Clinical Pharmacology
  • Japanese Society of Allergology

Zitieren

APA

Hirai, K., Shirai, T., Uehara, S., Akamatsu, T., & Itoh, K. (2025). Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.06.025

Vancouver

Hirai K, Shirai T, Uehara S, Akamatsu T, Itoh K. Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.06.025

BibTeX
@article{Hirai2025,
  author = {Hirai, Keita and Shirai, Toshihiro and Uehara, Sekiko and Akamatsu, Taisuke and Itoh, Kunihiko},
  title = {Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.jaci.2025.06.025}
}
Kostenlos starten →